Clinical trial · Interventional
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
Comparison of Single Session Transarterial Chemoembolization Combined With Microwave Ablation or Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study
NCT02646137CI-TRIAL-00031075unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for patients with surgically unresectable hepatocellular carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Microwave ablation combined with TACE | Procedure | — | UNRESOLVED |
| Radiofrequency ablation combined with TACE | Procedure | — | UNRESOLVED |
| Transarterial chemoembolization (TACE) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Transarterial chemoembolization (TACE)
- description
- treated by transarterial chemoembolization
- interventionNames
- Drug: Transarterial chemoembolization (TACE)
- type
- EXPERIMENTAL
- label
- Radiofrequency ablation with TACE
- description
- Radiofrequency ablation combined with TACE
- interventionNames
- Procedure: Radiofrequency ablation combined with TACE
- type
- EXPERIMENTAL
- label
- Microwave ablation combined with TACE
- description
- Microwave ablation combined with TACE.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Child classification A or B. * serum albumin ≥ 3 gm/L. * serum bilirubin \< 2.5 mg/dL. * platelet count ≥70,000 mm3. * INR ≤ 1.6. * serum creatinine \< 2 mg/dl. * tumor size more than 4 cm and confined to one lobe of the liver. Exclusion Criteria: * Patients with portal vein thrombosis. * A technically inaccessible hepatic artery. * Metastatic HCC. * More than three lesions. * lesions in close proximity to the portal vein (PV),inferior vena cava (IVC) or gall bladder were excluded from the study.
References
Publications (0)
Data not yet available
No reference posted for this study.